{"id":3892,"date":"2025-03-31T18:11:52","date_gmt":"2025-03-31T18:11:52","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/danaparoid-sodium-txt\/"},"modified":"2025-03-31T18:11:52","modified_gmt":"2025-03-31T18:11:52","slug":"danaparoid-sodium-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/danaparoid-sodium-txt\/","title":{"rendered":"Danaparoid sodium.txt"},"content":{"rendered":"

Danaparoid sodium<\/h1>\n

CLINICAL USE <\/H3>
\nProphylaxis of DVT and PE <\/p>\n
  • Thromboembolic disease requiring parenteral anticoagulation in patients with heparin induced thrombocytopenia (HIT)\n
  • Anticoagulation for haemodialysis

    DOSE IN NORMAL RENAL FUNCTION <\/H3>\n
  • Prophylaxis, DVT and PE: 750 units twice daily for 7\u201310 days (SC\n
  • HIT: 2500 units IV bolus (Wt90 kg: 3750 units) then an IV infusion of 400 units\/hour for 2 hours, 300 units\/hour for 2 hours, then 200 units\/hour for 5 days\n
  • Haemodialysis

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Approx 6500<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 40\u201350<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :8\u20139<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :25\/>31

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Use with caution
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use with caution. Reduce second and subsequent doses for thromboembolism prophylaxis

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR=10\u201320 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsEnhances effects of oral anticoagulants Interferes with laboratory monitoring of prothrombin time \u2013 monitor anticoagulation closely

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Glucose 5% or sodium chloride 0.9%

    Route <\/H4>SC, IV

    Rate of Administration <\/H4>See dose

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>\n
  • Pharmacokinetic information is from Pharm Update. 1997, Nov\/Dec; www.cc.nih.gov\/phar\/updates\/97 novdec.html\n
  • Monitor anti-Xa activity in patients >90 kg and with renal impairmentCan also be used for haemodialysis anticoagulation: 2\/3 times a week dialysis:\n
  • 1st and 2nd dialysis: 3750 units IV bolus prior to dialysis. (If patient weighs <55 kg then give 2500 unit IV bolus.)\n
  • Subsequent dialysis: 3000 units by IV bolus prior to dialysis, provided there are no fibrin threads in the bubble chamber. (If patient weighs <55 kg then give 2000 unit IV bolus.)\n
  • Daily dialysis:\n
  • 1st dialysis: 3750 units IV bolus prior to dialysis; if patient <55 kg give 2500 units\n
  • 2nd dialysis: 2500 units IV bolus prior to dialysis; if patient <55 kg give 2000 units\n
  • Prior to the second and subsequent dialysis a specimen should be drawn for plasma anti-Xa levels (to be used for dosing a third and subsequent dialysis)\n
  • Expected pre-dialysis ranges of anti-Xa levels:If plasma anti-Xa levels are <0.3 U\/ \u2014mL, then 3rd or subsequent dialysis dose should be 3000 units. For patients weighing <55 kg use 2000 unitsIf plasma anti-Xa levels are 0.3\u20130.35 \u2014U\/mL, then 3rd or subsequent dialysis dose should be 2500 units. For patients weighing <55 kg use 1500 unitsIf plasma anti-Xa levels are 0.35\u20130.4 \u2014U\/mL, then 3rd or subsequent dialysis dose should be 2000 units. For patients weighing 0.4 U\/mL, \u2014then do not give any danaparoid before dialysis. However, if fibrin threads form in the bubble chamber, then the patient may be given 1500 units IV bolus (irrespective of the patient\u2019s weight)During dialysis the plasma anti-Xa level should be between 0.5\u20130.8 U\/mLIf needed take a blood sample prior to every dialysis and during dialysis (at 30 minutes and at 4 hours)Alternative regime for\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : (New Zealand data sheet): infusion of 600 units\/hour for 4 hours then 200\u2013600 units\/hour to maintain anti-Xa levels of 0.5\u20131 U\/mL. If patient <55 kg then use 400 units\/hour for 4 hours then 150\u2013400 units\/hourProtamine is no use as an antidote for bleeding complications. If no anti-Xa monitoring is available then the first 4 dialysis sessions should have pre-dialysis IV bolus of 3750, 3750, 3000 and 2500 units respectively, then 2500 units thereafter. Take blood sample prior to 4th and 7th dialysis to ensure there is no accumulationOozing from puncture sites has been noted 24\u201336 hours post doseFor CVVH, an initial bolus of 750 units followed by an infusion of 0.7\u20132 units\/kg\/hr can be given. (Wester JPJ. Guidelines for anticoagulation with danaparoid sodium and lepirudin in continuous venovenous hemofiltration.
    \n","protected":false},"excerpt":{"rendered":"

    Danaparoid sodium CLINICAL USE Prophylaxis of DVT and PE Thromboembolic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3892","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3892"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3892\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}